Burning Rock Biotech (NASDAQ:BNR) Director Yusheng Han Purchases 210,000 Shares

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han acquired 210,000 shares of the firm’s stock in a transaction on Friday, June 12th. The shares were bought at an average cost of $9.25 per share, with a total value of $1,942,500.00. Following the completion of the transaction, the director directly owned 17,907,436 shares in the company, valued at $165,643,783. This trade represents a 1.19% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The stock was bought at an average cost of $8.00 per share, for a total transaction of $199,200.00.
• On Wednesday, June 24th, Yusheng Han purchased 250,000 shares of Burning Rock Biotech stock. The shares were bought at an average price of $8.00 per share, with a total value of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han purchased 5,990 shares of Burning Rock Biotech stock. The shares were bought at an average price of $7.50 per share, with a total value of $44,925.00.
• On Monday, June 22nd, Yusheng Han purchased 104,650 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $7.45 per share, with a total value of $779,642.50.
• On Tuesday, June 16th, Yusheng Han acquired 111,110 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $9.00 per share, for a total transaction of $999,990.00.
• On Thursday, June 11th, Yusheng Han acquired 24,760 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $8.74 per share, for a total transaction of $216,402.40.

Burning Rock Biotech Stock Performance

Shares of BNR opened at $9.82 on Friday. The stock has a market capitalization of $103.31 million, a P/E ratio of -11.98 and a beta of 1.32. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.81 and a current ratio of 3.05. Burning Rock Biotech Limited Sponsored ADR has a 1 year low of $3.23 and a 1 year high of $41.72. The company’s fifty day moving average is $12.57 and its two-hundred day moving average is $20.04.

Burning Rock Biotech (NASDAQ:BNR) last released its earnings results on Tuesday, June 9th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($2.29) by $2.09. The company had revenue of $15.66 million during the quarter, compared to analysts’ expectations of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.

Hedge Funds Weigh In On Burning Rock Biotech

A number of large investors have recently made changes to their positions in the stock. Crcm LP lifted its stake in shares of Burning Rock Biotech by 13.8% in the third quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after purchasing an additional 26,809 shares during the period. Marshall Wace LLP acquired a new position in Burning Rock Biotech during the fourth quarter worth about $220,000. Renaissance Technologies LLC grew its position in Burning Rock Biotech by 13.8% during the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after buying an additional 4,290 shares during the period. Finally, Prospera Financial Services Inc increased its holdings in Burning Rock Biotech by 26.0% in the fourth quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after buying an additional 6,430 shares in the last quarter. Hedge funds and other institutional investors own 30.03% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on BNR. Wall Street Zen lowered Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.